Recent Company News

• 12:13 AM ET Oct 13, 2025
  

  Hutchmed to present results from phase III part of FRUSІCA-2 trial for renal cell carcinoma on 17-Oct at ESMO Congress (HK$23.52, -1.22)

• 11:05 PM ET Sep 04, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 05:06 PM ET Sep 22, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 05:52 PM ET Sep 21, 2025
  

  Morgan Stanley downgrades Hutchmed (13.HK, HCM)

• 09:30 AM ET Sep 08, 2025
  

  Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

• 09:21 AM ET Sep 05, 2025
  

  StreetAccount Summary - US Pre-market trading update